Stage IV Non-Small Cell Lung Cancer: Jill's Patient Story

Patient Info: Jill, Female, 50s | Stage IV

Biomarkers: Driver mutation identified; specific mutation not stated

Metastatic Site: pleura

As of May 2026, Jill had lived 17 years with NSCLC, later experienced pleural metastases/progression, and remained on biomarker-guided targeted therapy with chemotherapy added.

The Patient StoryRead more →

EGFR-mutated lung cancer responds after acquired ROS1 resistance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; acquired ROS1 rearrangement

Metastatic Site: pleura

She remained on osimertinib plus crizotinib with a sustained clinical and radiologic response for more than 18 months.

PubMed CentralRead more →

Stage IV EGFR-mutated lung cancer responds after targeted therapy intolerance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; PIK3CA E545K mutation; acquired ROS1 rearrangement

Metastatic Site: pleura|pericardium|bone|lungs

Chemotherapy produced a partial response that remained sustained for 7 months at the latest follow-up.

PubMed CentralRead more →

EGFR-mutated Stage IV lung cancer with later brain progression

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR C797S mutation; acquired ROS1 rearrangement

Metastatic Site: brain|bone

She died about 20 months after diagnosis after brain progression and a severe postoperative stroke.

PubMed CentralRead more →

Stage IV ALK Lung Cancer: Jake's Patient Story

Patient Info: Jake, Male, Under 40 | Stage IV

Biomarkers: ALK-positive mutation

Metastatic Site: brain; lung; ankle bone

As of May 2026, Jake was 28 and had lived more than 13 years with Stage IV ALK-positive lung cancer, with ongoing treatment history including targeted therapy, surgeries, radiation, clinical-trial therapy, and recent chemotherapy.

The Patient StoryRead more →

Stage IV ALK Lung Cancer: Kartik's Patient Story

Patient Info: Kartik, Male, Under 40 | Stage IV

Biomarkers: EML4/ALK mutation

Kartik was diagnosed with Stage IV ALK-rearranged lung cancer at age 28, continued working for several years through a targeted clinical trial, and died in 2015 at age 34.

GO2 FoundationRead more →

Stage IVA EGFR-mutated lung adenocarcinoma: stable disease on first-line osimertinib

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: EGFR exon 19 deletion; baseline EGFR exon 20 T790M mutation; ALK IHC negative; PD-L1 TPS 30%; TTF-1-positive

Metastatic Site: pleura; malignant pleural-pericardial adhesions

As of April 2026, she had stable disease for more than 9 months on first-line osimertinib, with no progressive disease, no recurrent pleural effusion, ECOG improvement from 2 to 0, and no treatment-related adverse events.

PubMed CentralRead more →

Stage II Lung Cancer: Michelle's Patient Story

Patient Info: Michelle, Female | Stage II

Receiving ongoing adjuvant treatment after lung cancer first thought to be Stage I was upgraded to Stage IIB because 3 of 18 lymph nodes were positive.

The Patient StoryRead more →

Stage IV EGFR Lung Cancer: Kelsey's Patient Story

Patient Info: Kelsey, Female, Under 40 | Stage IV

Biomarkers: EGFR mutation; later ALK mutation after progression

Metastatic Site: Bone — pelvis and spine/L5

Living with Stage IV lung cancer on a clinical trial after progression, with current treatment described as working and quality of life improved.

The Patient StoryRead more →

Stage II EGFR Non-Small Cell Lung Cancer: Daniel's Patient Story

Patient Info: Daniel West, Male, 50s | Stage II

Biomarkers: EGFR positive

As of April 2026, Daniel had shown no evidence of active disease for more than 2 years, while remaining on daily osimertinib through June 2026 and receiving checkups and scans every 3 months for stable monitored lung nodules.

MD AndersonRead more →

Stage IV ALK Non-Small Cell Lung Cancer: Megan's Survivor Story

Patient Info: Megan, Female, Under 40 | Stage IV

Biomarkers: ALK-positive

Metastatic Site: Spine; chest lymph nodes; stomach lymph nodes

Stage IV ALK-positive non-small cell lung cancer responded dramatically to daily targeted therapy, with latest scans described as no evidence of disease while she continues long-term targeted therapy.

The Patient StoryRead more →

Stage III EGFR Lung Cancer: Roxanne's Patient Story

Patient Info: Roxanne, Female, 40s | Stage III

Biomarkers: EGFR mutation

Roxanne had Stage III EGFR-mutated lung cancer after surgery found mediastinal lymph-node involvement. As of March 2026, she was living with the long-term effects of surgery, chemotherapy, radiation, and ongoing EGFR-targeted therapy, while also managing the emotional and financial burden of cancer as a single parent.

The Patient StoryRead more →

Targeted therapy made Stage III ALK-positive lung cancer operable

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: ALK-positive; PD-L1 high

Surgery found no residual cancer, and follow-up scans showed no recurrence through 15 months.

PubMed CentralRead more →

Stage IV EGFR-positive lung cancer treated for nearly 5 years before progression

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR L858R mutation

Metastatic Site: liver

The cancer later progressed despite chemotherapy, and he died from lung cancer 4 years and 8 months after diagnosis.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Maggie's Patient Story

Patient Info: Maggie, Female, 60s | Stage IV

Biomarkers: EGFR mutation; MET amplification resistance mutation; MET overexpression

Metastatic Site: Brain

Maggie initially reached no evidence of disease on EGFR-targeted therapy, but later had repeated progression, including MET-amplification resistance and MET overexpression, requiring SBRT, a clinical trial, chemotherapy, and later-line targeted treatment.

The Patient StoryRead more →

Stage IV ALK Non-Small Cell Lung Cancer: Clara's Patient Story

Patient Info: Clara, Female, Under 40 | Stage IV

Biomarkers: ALK-positive / ALK-rearranged after repeat Tempus testing

Metastatic Site: Pelvis; spleen

As of February 2026, ALK-targeted therapy had improved Clara’s symptoms enough that she no longer needed a walker or cane, and upcoming scans would determine whether pelvic tumor surgery remained an option.

The Patient StoryRead more →

Stage IV ROS1 Lung Cancer: Phil's Patient Story

Patient Info: Phil, Male, 60s | Stage IV

Biomarkers: ROS1 mutation

Metastatic Site: Lymph nodes; other lung

Phil was living with incurable Stage IV ROS1-positive lung cancer. After initial chemotherapy, a ROS1-targeted pill worked for about 2 years, and he later continued on a Mass General clinical-trial treatment with follow-up every 3 months.

The Patient StoryRead more →

Pulmonary epithelioid hemangioendothelioma with complete response after neoadjuvant therapy

Patient Info: Anonymized, Male, 60s

Biomarkers: WWTR1-CAMTA1 fusion; vascular markers supported epithelioid hemangioendothelioma; lung cancer markers were absent.

The patient achieved radiographic disappearance of the lung tumor after neoadjuvant paclitaxel/carboplatin plus bevacizumab. Surgery then showed no residual tumor and lymph nodes were negative; CT follow-up through April 2024 showed no recurrence.

PubMed CentralRead more →

Stage IV ALK Non-Small Cell Lung Cancer: Stephanie's Patient Story

Patient Info: Stephanie, Female, 40s | Stage IV

Biomarkers: ALK mutation / ALK-positive

Metastatic Site: ovaries; spine; liver; lung

Stage IV ALK-positive NSCLC is being managed with ALK-directed treatment; follow-up scans were described as improving, but the source does not state complete remission.

The Patient StoryRead more →

EGFR L858R lung adenocarcinoma with rapid neurologic decline

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: EGFR L858R mutation; CK7-positive; Napsin A-positive; TTF-1-positive; p40-negative; Ki-67 about 1%

Metastatic Site: brain parenchyma and meninges

The patient developed rapidly progressive cognitive decline with multifocal brain lesions. Lung biopsy confirmed EGFR L858R lung adenocarcinoma, and she received amivantamab, but neurologic deterioration continued and she died in the fourth month of the disease course.

PubMed CentralRead more →

Stage IV ALK Lung Cancer: Ruchira's Survivor Story

Patient Info: Ruchira, Female | Stage IV

Biomarkers: ALK-positive

Metastatic Site: Not reported

Although the disease progressed to Stage IV after lobectomy, ALK testing led to lorlatinib; she reported no evidence of disease after 3 months and continued daily targeted therapy.

The Patient StoryRead more →

BRAF-mutant stage IV lung adenocarcinoma complicated by immunotherapy-induced diabetes

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: BRAF mutation; GADA-positive during immune-related diabetes evaluation

Metastatic Site: left lower lung, pleural

The patient had Stage IV BRAF V600E-mutant lung adenocarcinoma treated with targeted therapy and later tislelizumab. Immunotherapy was suspended after hypoadrenocorticism and diabetic ketosis; she required ongoing insulin therapy, with persistently low C-peptide at 6-month follow-up.

PubMed CentralRead more →

EGFR-mutant lung adenocarcinoma with acquired ROS1 rearrangement after EGFR-TKI resistance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M; acquired EZR exon10-ROS1 exon34 rearrangement

Metastatic Site: bone (distal femur); contralateral lung;…

After fourth-line crizotinib for acquired EZR-ROS1 rearrangement, response evaluation on August 27, 2025 showed partial response, and September 2025 bone scan showed stable bone lesions.

PubMed CentralRead more →

Stage 4 lung cancer: never-smoker with complete remission

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR20ins mutation; TP53 p.Q192 mutation; PD-L1 TPS 0%; CPS 0%

Metastatic Site: bilateral lungs, mediastinal lymph nodes, bilateral…

The patient had a durable response to high-dose furmonertinib, later developed a right cerebellar metastasis treated with stereotactic radiation, and continued to benefit from furmonertinib as of April 2025 with 27 months of progression-free survival reported.

PubMed CentralRead more →